AI's impact isn't just job replacement; it's fostering a new internal economy within pharma, leading to a 'renaissance' of roles. These are not future concepts but current job postings for positions like 'Translational AI scientists' and 'Regulatory AI officers.' The real opportunity is not just defending one's current job but moving into these emerging, high-growth functions.
Related Insights
With over half of new startup pitches focusing on AI automating existing jobs, the primary solution to this massive displacement is not retraining, but fostering an ecosystem that aggressively creates new companies, new industries, and consequently, new roles.
Career security in the age of AI isn't about outperforming machines at repetitive tasks. Instead, it requires moving 'up the stack' to focus on human-centric oversight that AI cannot replicate. These indispensable roles include validation, governance, ethics, data integrity, and regulatory AI strategy, which will hold the most influence and longevity.
Martin Shkreli argues that the primary bottleneck in drug development isn't finding new molecules, but the immense inefficiency caused by poor communication, irrational decision-making, and misaligned incentives across numerous human departments. He believes AI's greatest contribution will be optimizing this complex organizational process rather than just improving discovery.
Rather than just replacing jobs, AI is fostering the emergence of new, specialized roles. The "Content Automation Strategist," for example, is a position that merges creative oversight with the technical skill to use AI for scaling content production and personalization effectively.
The focus on AI automating existing human labor misses the larger opportunity. The most significant value will come from creating entirely new types of companies that are fully autonomous and operate in ways we can't currently conceive, moving beyond simple replacement of today's jobs.
The fear that AI will eliminate jobs in fields like law is misplaced. While it automates low-level tasks, it also enables clients to grow faster and create more complex products. This generates a new wave of demand for high-level advisory on emerging issues like AI risk and global regulations.
AI will create jobs in unexpected places. As AI accelerates the discovery of new drugs and medical treatments, the bottleneck will shift to human-centric validation. This will lead to significant job growth in the biomedical sector, particularly in roles related to managing and conducting clinical trials.
AI will handle most routine tasks, reducing the number of average 'doers'. Those remaining will be either the absolute best in their craft or individuals leveraging AI for superhuman productivity. Everyone else must shift to 'director' roles, focusing on strategy, orchestration, and interpreting AI output.
According to Immunocore's CEO, the biggest imminent shift in drug development is AI. The critical need is not for AI to replace scientists, but for a new breed of professionals fluent in both their scientific domain and artificial intelligence. Those who fail to adapt will be left behind.
Rather than simply eliminating jobs, the rise of AI agents is creating a need for new, specialized roles. Positions like "Go-to-Market Engineer" and "AI Marketing Ops Specialist" are emerging to oversee, coach, and orchestrate these agents, signaling a transformation—not a reduction—of the GTM workforce.